Roche Building Alternate-Site Diabetes Testing Capability Via Amira
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics will leverage Amira Medical's alternate-site blood glucose testing technology in order to increase its presence in the integrated spot monitoring (ISM) market
You may also be interested in...
Alternate-Site Glucose Test Developers Share Clinical Experience With FDA
TheraSense will present clinical data related to its FreeStyle alternate-site blood glucose monitoring system to FDA's Center for Devices and Radiological Health Oct. 19 to help the agency consider labeling options for such devices.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.